Open-Label Pilot Trial of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis- Associated Active Interstitial Lung Disease (SSc-ILD)

PURPOSE: Transforming growth factor-beta (TGF-b) and platelet-derived growth factor (PDGF) may play a critical role in systemic sclerosis- interstitial lung disease (SSc-ILD) and imatinib is a potent inhibitor of TGF-b and PDGF production. We report a phase I/IIa open-label pilot study of imatinib i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Khanna, Dinesh, Saggar, Rajeev, Mayes, Maureen D., Abtin, Fereidoun, Clements, Philip J., Maranian, Paul, Assassi, Shervin, Saggar, Rajan, Singh, Ram R., Furst, Daniel E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3205223/
https://ncbi.nlm.nih.gov/pubmed/21769849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.30548
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados